Grand Pharmaceutical Enrolls First Patient in China Phase II Trial of Migraine Drug GPN01020PUBT·Nov 10, 2026 at 09:59 AM00512-0.35%
Grand Pharmaceutical’s CBT-001 Meets Phase III Pterygium EndpointTip Ranks·Nov 5, 2026 at 12:37 AM00512-0.35%
Grand Pharmaceutical Says Overseas Expansion Drives Proposed Switch to Deloitte as AuditorPUBT·Nov 3, 2026 at 12:17 PM00512-0.35%
Hong Kong Healthcare Stocks Split: Far Eastern Pharma's FDA Gamble vs. Real Estate QuagmireGlobal Report·Oct 28, 2026 at 10:14 AM01515-2.22%008530.00%